Journal Article

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome

Ivanova, Karina A., Meshcheryakov, Fedor A., Telegin, Georgii B., Rodionov, Maksim V., Kudriaeva, Anna A., Kazakov, Vitaly A., Chernov, Aleksandr S., Gabibov, Alexander G., Belogurov, Alexey A.

2024

Overview

Introduction: The acute respiratory distress syndrome (ARDS), secondary to viral pneumonitis, is one of the main causes of high mortality in patients with COVID-19 (novel coronavirus disease 2019)—ongoing SARS-CoV-2 infection— reached more than 0.7 billion registered cases. Methods: Recently, we elaborated a non-surgical and reproducible method of the unilateral total diffuse alveolar damage (DAD) of the left lung in ICR mice–a publicly available imitation of the ARDS caused by SARS-CoV-2. Our data read that two C–C chemokine receptor 5 (CCR5) ligands, macrophage inflammatory proteins (MIPs) MIP-1α/CCL3 and MIP-1β/CCL4, are upregulated in this DAD model up to three orders of magnitude compared to the background level. Results: Here, we showed that a nonpeptide compound TAK-779, an antagonist of CCR5/CXCR3, readily prevents DAD in the lung with a single injection of 2.5 mg/kg. Histological analysis revealed reduced peribronchial and perivascular mononuclear infiltration in the lung and mononuclear infiltration of the wall and lumen of the alveoli in the TAK-779-treated animals. Administration of TAK-779 decreased the 3–5-fold level of serum cytokines and chemokines in animals with DAD, including CCR5 ligands MIP-1α/β, MCP-1, and CCL5. Computed tomography revealed rapid recovery of the density and volume of the affected lung in TAK-779-treated animals. Discussion: Our pre-clinical data suggest that TAK-779 is more effective than the administration of dexamethasone or the anti-IL6R therapeutic antibody tocilizumab, which brings novel therapeutic modality to TAK-779 and other CCR5 inhibitors for the treatment of virus-induced hyperinflammation syndromes, including COVID-19.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: acute respiratory distress syndrome / Alveoli / Animal models / CC chemokine receptors / CCR5/CXCR3 / Chemokine receptors / Chemokines / Computed tomography / Coronaviruses / COVID-19 / CXCR3 protein / Cytokine storm / Dexamethasone / diffuse alveolar damage of the lung / Drug dosages / Immune response / Infections / Interleukin 6 receptors / Kinases / Ligands / Lungs / Lymphocytes / Macrophages / Monoclonal antibodies / Monocyte chemoattractant protein 1 / Mortality / Neutrophils / Pandemics / Pharmacology / Pneumonitis / Respiratory distress syndrome / RNA polymerase / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / TAK-779